Chronic immune-related adverse events with anti–PD-1 therapy are more common than previously recognised and may persist unresolved, new research shows. While most irAEs with anti–PD-1 therapy occur in visceral organs in the first 12 weeks of treatment, almost half of patients may also develop chronic low-level irAEs in non-visceral organs, according to a study that ...
Chronic irAEs common with anti–PD-1 therapy
By Michael Woodhead
26 Mar 2021